IPM Take
This is early, and it must be treated as early. But it is also the kind of signal that challenges the architecture of cell therapy. CAR-T has changed myeloma, yet it remains heavy medicine: cell collection, manufacturing queues, lymphodepletion, specialist centres and high cost. KLN-1010 asks a bigger question: what if the CAR-T cell could be generated inside the patient? If that works in larger studies, access politics changes completely.
Executive Summary
Targeted Oncology reported in June 2026 that KLN-1010, an in vivo BCMA CAR-T approach for relapsed/refractory multiple myeloma, achieved a 100% overall response rate and 100% MRD negativity among evaluable patients in preliminary phase 1 data presented at the EHA 2026 Congress. Kelonia previously reported updated ASCO 2026 inMMyCAR data showing 18 patients dosed, 100% overall response and MRD-negative bone marrow at one month in evaluable patients, a 13-day median time from consent to infusion, CAR-T expansion without lymphodepleting chemotherapy, and safety review committee approval for outpatient infusion. These findings are early and require longer follow-up, larger cohorts and careful safety evaluation.
Why it matters
- Cell therapy centres: In vivo CAR-T could challenge the current manufacturing-heavy model, but durability and safety must be proven.
- Regulators: A new delivery model will require careful evidence standards around persistence, toxicity and comparability to ex vivo CAR-T.
- Payers: If validated, shorter logistics and reduced manufacturing burden could reshape value assessment.
- Patients: Faster, less complex CAR-T delivery could matter deeply, but early signals should not be confused with established access.
CAR-T has already changed multiple myeloma. The problem is that access has not changed nearly enough.
Today’s cell therapy pathway is heavy. Patients may need cell collection, external manufacturing, bridging therapy, lymphodepletion, specialist centre availability and prolonged monitoring. For many systems, CAR-T is not just a therapy. It is a capacity bottleneck.
KLN-1010 points to a different model. It is designed as an in vivo CAR-T approach. Instead of removing a patient’s cells, engineering them outside the body and reinfusing them, the therapy aims to generate anti-BCMA CAR-T cells inside the patient.
That is why the early data are important, even if they remain preliminary. The reported response and MRD-negativity signals are striking. So is the access implication: Kelonia reported a 13-day median time from consent to infusion and CAR-T expansion without lymphodepleting chemotherapy. If confirmed, this could reduce some of the logistical barriers that define today’s cell therapy systems.
The caution must stay loud. This is phase 1 evidence with limited follow-up. It is not a new standard of care. In vivo engineering brings its own safety, regulatory and durability questions.
For IPM, the signal is powerful because it asks the right access question: not only which target should cell therapy hit, but whether the entire manufacturing model can be redesigned so more patients can realistically reach it.
